tbuckley/cabot-search huggingface dataset:
NIMG-28. PRESENCE OF HIGH ADC (LOW CELLULARITY) TUMOR REGIONS INCREASES WITH DIFFUSE APPEARANCE OF GBMs ON ROUTINE MRI
Authors: Pamela Jackson, Andrea Hawkins-Daarud, Joshua Jacobs, Hani Malone, Timothy Ung, Joo Kim, Olya Stringfield, Lauren DeGirolamo, Emilio Benbassat, Anthony Rosenberg, Joseph Crisman, Robert Gatenby, Savannah Partridge, Peter Canoll, Kristin Swanson
Journal: Neuro-Oncology (2016)

The Proliferation-Invasion (PI) tumor mathematical model provides a rubric to estimate glioblastoma (GBM) growth in terms of patient-specific net proliferation and net invasion rates. The apparent diffusion coefficient (ADC), calculated from diffusion-weighted magnetic resonance imaging (MRI), is believed to be predictive of tumor cellularity and microstructure. Our goal was to investigate how well the PI model-derived invasiveness index (D/ρ) compares to the distribution of ADC values within the tumor. T1Gd and FLAIR images were segmented for twelve patients with contrast-enhancing GBMs. A FLAIR penumbra region of interest (ROI) was created by subtracting the T1Gd and FLAIR ROIs. These ROI’s were then used to mask the co-registered ADC maps. The resulting ADC histogram from the FLAIR ROI was fit using a bimodal Gaussian model. We calculated the percent of ADC voxels classified as being below each peak, within the lower or upper peak, within both peaks, or above the peaks. The PI model relates tumor cell density to tumor cell dispersal (D) and proliferation (ρ) and is parameterized with the T1Gd and FLAIR ROIs. Higher D/ρ tumors are considered more invasive than lower D/ρ tumors. D/ρ was negatively correlated with percent of voxels below the lower peak for both T1Gd and FLAIR ROIs (p<0.001 and p=0.004, respectively) and positively correlated the percent of voxels above the upper peak percent for the T1Gd ROI (p=0.002). Consistent with low D/ρ representing highly cellular (less diffuse) tumors, we observed an increased presence of low ADC, and thus high cellularity, regions within low D/ρ tumors. Analogously, for tumors with a more diffuse phenotype (high D/ρ), we observed an increased presence of high ADC (low cellularity) regions within the tumor. Understanding the relationship between D/ρ and ADC allows us to connect observations on multiparametric imaging and elucidate the tumor biology.
David Oliver: Hotel chains are no answer to hospital bed crises
Authors: David Oliver
Journal: BMJ (2017)

Roy Lilley, the ubiquitous health pundit, wrote in January of the need for radical solutions to current NHS crises rather than medical colleges endlessly campaigning for more resources.1

Lilley then set out some big, audacious ideas of his own. One was that, to “get the thousands [of people] marooned in hospital home safely,” we should “Block-book Premier Inns; create step-down care. It’s £45 a night. Include a matron and some care assistants and you’ll do it for £150. Hospitals cost £400.”2

Does this idea bear scrutiny? Who are these patients stranded in hospital, and will it …
Anthracycline mediated cardiotoxicity: Detection of miRNA based early biomarkers for the prediction of myocardial injury. Hecatos study
Authors: C. Salvador Coloma, P. Sepúlveda, A. Hernandiz, S. Tejedor, L. Palomar, A. Ruiz, V. Miro, H.l.a. De Cueva, I. Ontoria-Oviedo, A. Salvador, V. Castel, A. Santaballa
Journal: Annals of Oncology (2016)
CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC
Authors: Patrice Chevallier, Myriam Labopin, Regis Peffault de la Tour, Bruno Lioure, Jean-Yves Cahn, Anne Huynh, Didier Blaise, Pascal Turlure, Eric Deconinck, Natacha Maillard, Ibrahim Yakoub-Agha, Gaelle Guillerm, Nathalie Fegueux, Nathalie Contentin, Jacques-Olivier Bay, Florence Beckerich, Jean-Henri Bourhis, Marie Y. Detrait, Stephane Vigouroux, Sylvie François, Faezeh Legrand, Nicole Raus, Thierry Guillaume, Mohamad Mohty
Journal: Blood (2015)
Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis
Authors: Benjamin Ruprecht, Esther A. Zaal, Jana Zecha, Wei Wu, Celia R. Berkers, Bernhard Kuster, Simone Lemeer
Journal: Cancer Research (2017)

HER2/ERBB2-overexpressing breast cancers targeted effectively by the small-molecule kinase inhibitor lapatinib frequently acquire resistance to this drug. In this study, we employed explorative mass spectrometry to profile proteome, kinome, and phosphoproteome changes in an established model of lapatinib resistance to systematically investigate initial inhibitor response and subsequent reprogramming in resistance. The resulting dataset, which collectively contains quantitative data for >7,800 proteins, >300 protein kinases, and >15,000 phosphopeptides, enabled deep insight into signaling recovery and molecular reprogramming upon resistance. Our data-driven approach confirmed previously described mechanisms of resistance (e.g., AXL overexpression and PIK3 reactivation), revealed novel pharmacologically actionable targets, and confirmed the expectation of significant heterogeneity in molecular resistance drivers inducing distinct phenotypic changes. Furthermore, our approach identified an extensive and exclusively phosphorylation-mediated reprogramming of glycolytic activity, supported additionally by widespread changes of corresponding metabolites and an increased sensitivity towards glycolysis inhibition. Collectively, our multi-omic analysis offers deeper perspectives on cancer drug resistance and suggests new biomarkers and treatment options for lapatinib-resistant cancers. Cancer Res; 77(8); 1842-53. ©2017 AACR.
Synchrony between suprachiasmatic nucleus‐driven signals and the light/dark cycle is essential for liver homeostasis
Authors: Ruud M. Buijs, Natali Guerrero‐Vargas
Journal: Hepatology (2017)

1Department of Cell Biology and Physiology, Institute for Biomedical Research, Universidad Nacional Autónoma de México, UNAMMéxico CityMéxico 2Department of Anatomy, Faculty of Medicine, Universidad Nacional Autónoma de México, UNAMMéxico CityMéxico
EXTH-55. PRECLINICAL EVALUATION OF NT113, A NOVEL IRREVERSIBLE PAN-ErbB INHIBITOR OPTIMIZED FOR CNS BIODISTRIBUTION
Authors: Dennis Brown, Charles David James, Nicholas Arthur Butowski, Timothy F. Cloughesy, Yuki Yoshida, Tomoko Ozawa, Wang Shen, Harry Pedersen
Journal: Neuro-Oncology (2016)

Deregulated ErbB signaling is associated with the development of solid tumors including glioblastoma (GBM), of which approximately 45% have EGFR amplification and/or mutation. Unfortunately, small molecule inhibitors targeting ErbB receptors have not demonstrated significant anti-tumor activity against GBM in clinical settings, irrespective of tumor EGFR status, with clinical efficacy undoubtedly compromised by poor CNS penetration of ErbB inhibitors used to date. NT113 is an irreversible pan-ErbB inhibitor that has excellent CNS penetration with accumulation in brain. Oral administration of NT113 results in significant brain exposure in pharmacokinetic (PK) studies, with brain/plasma ratios > 4, at two, four and twenty-four hour time points post administration. If NT113 rodent PK results are realized in patients, it may promote significant clinical activity in treating intracranial tumors with ErbB signaling dependency. Consistent with this possibility, results from a preliminary patient derived xenograft (PDX) study involving the treatment of mice with intracranial EGFRvIII mutant GBM xenograft tumor, NT113 completely suppressed tumor growth for a two-week period of NT113 administration and significantly prolonged the lifespan of treated mice. A second PDX experiment, involving the use of a tumorigenic GBM cell source with amplification of wild-type EGFR, again showed potent NT113 anti-proliferative activity against tumor, and significantly extended animal survival. In this second experiment, NT113 also significantly outperformed both erlotinib and lapatinib, with each therapeutic administered at its daily MTD for athymic mice. Furthermore, results from in vitro studies indicate that NT113 has activity against GBM cell lines lacking amplification of EGFR. In total, our data support the possibility of NT113 being a “best-in-class” pan-ErbB inhibitor for the treatment of ErbB driven GBM and, additionally, GBM lacking EGFR amplification.
Accuracy of plasma RAS mutation testing for therapy selection and monitoring of colorectal cancer patients
Authors: J. Vidal Barrull, L. Muinelo Romay, A. Dalmases, A. Abalo, M.C. Vela, M. Abreu Rodríguez, M. Muset, J. Ruiz, M. Iglesias, C. Blanco, E. López, C. Rodríguez, F.S. Jones, D. Edelstein, A. Lukas, J. Albanell, B. Bellosillo, S. Candamio, C. Montagut, R. López
Journal: Annals of Oncology (2016)
Quantification of Recent Bone Marrow B-Cell and Thymic T-Cell Emigrants in Chemotherapy Naïve Patients with Chronic Lymphocytic Leukemia.
Authors: Marina Motta, Claudia Ghidini, Cinzia Zanotti, Marco Chiarini, Luigi Caimi, Luisa Imberti, Elisa Cerqui, Monica Drera, Giuseppe Rossi
Journal: Blood (2009)
Methotrexate chemotherapy in elderly patients with locally advanced head and neck cancer: preliminary results
Authors: G. Rinaldi, D. Galanti, A. Stagno, E. Bronte, A. Marchese, G. Badalamenti, M. Semprevivo, L. Terruso, V. Vanella, I. Alessi, F. Fulfaro, A. Malfitano, A. Cordova, V. Albanese, C. Volpe, L. Incorvaia, A. Russo
Journal: Annals of Oncology (2016)
Rituximab Plus Dose Intense Rapid-Cycling Chemotherapy with Intrathecal CNS Prophylaxis in Patients with Burkitt Lymphoma (BL) and Intermediate Unclassifiable Diffuse Large B-Cell Lymphoma/BL: Single Institution Experience
Authors: Chiara Frairia, Chiara Ciochetto, Ernesta Audisio, Giulia Benevolo, Barbara Botto, Annalisa Chiappella, Maura Nicolosi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, Filippo Marmont, Umberto Vitolo
Journal: Blood (2011)
Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.
Authors: Francine Foss, Nelida Sjak-Shie, Andre Goy, Eric Jacobsen, Ranjana Advani, Mitchell Smith, Rami Komrokji, Kelly Pendergrass, Vanessa Bolejack, Karen Watts, Mark Acosta
Journal: Blood (2007)
Encouraging Results of Reduced-Intensity Conditioning (RIC) Followed by Hematopoietic Stem Cell Transplantation (HSCT) from an Alternative Donor for Acute Lymphoblastic Leukemia (ALL) In Children.
Authors: Masami Inoue, Masahiro Yasui, Sadao Tokimasa, Akihisa Sawada, Maho Sato, Osamu Kondo, Kayo Yamada, Keisei Kawa
Journal: Blood (2010)
Defective Telomerase in Familial Myelodysplasia and Leukemia
Authors: Michael Kirwan, Tom Vulliamy, Amanda J. Walne, Richard Beswick, Peter Hillmen, Richard Kelly, Andrew Stewart, David Bowen, Stefan Schonland, Annika Maria Whittle, Tony McVerry, Maria Gilleece, Inderjeet Dokal
Journal: Blood (2008)
Aesthetic and Functional Improvement of Chronic Radiation Dermatitis With Noninsulated Microneedle Fractional Radiofrequency
Authors: Derek Ho, Ekaterina Kraeva, Joshua M. Schulman, Jared Jagdeo
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Authors’ reply to Aiyenigba and Weeks, Bahadur and colleagues, and Griffin and colleagues
Authors: Carl Heneghan, Elizabeth Spencer, Ben Goldacre
Journal: BMJ (2017)

Aiyenigba and Weeks appropriately highlight the social and psychological aspects of fertility treatments, with particular reference to sub-Saharan Africa.1 They describe the need to involve patients first and foremost in determining health service provision, while providing evidence to help decision making—the practice of evidence based healthcare. They underline our point that, whereas we found high variability and lack of evidence provision in fertility services offered in the UK, the situation is likely to be worse where there is less regulation.23

Bahadur and colleagues draw attention to the current confusion in guidance and shortcomings in current guidelines from the National Institute for Health and Care Excellence (NICE).4 We agree that …
Abiraterone acetate as first-line treatment for CRPC
Authors: Hiroyoshi Suzuki, Takanobu Utsumi, Takumi Endo, Seiji Kato, Takatoshi Soumoto, Ken Wakai, Ryo Oka, Masashi Yano, Shuichi Kamijima, Naoto Kamiya
Journal: Annals of Oncology (2016)
RTHP-23. Cs131 IMPLANTS FOR SALVAGE THERAPY OF RECURRENT HIGH GRADE GLIOMAS (HGG)
Authors: Emad Youssef, Theresa Thomas, Heyoung McBride, Peter Nakaji, Kris Smith, David Brachman
Journal: Neuro-Oncology (2016)

We report our initial experience using Cs131 brachytherapy seeds in the adjuvant setting after resection of recurrent HGG. Thirteen patients with recurrent HGG status post resection, external beam radiation and chemotherapy, were treated using surgical resection and placement of Cs 131 brachytherapy seeds. Average age at the time of implant was 60 years (range 36-80). Nine and four patients had WHO Grade 4 and 3 respectively. Eleven and two patients had cerebral and cerebellar tumors respectively. Cs 131seeds (range of 9-38) were used to deliver 60 Gy at 5 mm from the tumor bed after surgical resection. Overall Survival was calculated from the time of implant till the time of death. Treatment failure was defined radiographically by area of new Gadolinium enhancement on follow up MRI. Serial imaging, perfusion scans or both were used to differentiate recurrence from post therapy changes. Failure was considered to be local if it happened within 2 cm of the implant bed and distant if beyond 2 cm from the implant bed. At the time of analysis; six patients were alive. Median overall survival for the whole group and the living patients was 5.2 months (range: 0.13 to 23.45 months and 0.53 to 23.45 months for the whole group and living patients respectively). Two patients died in the immediate postoperative period of unrelated operative complications and were excluded from the treatment failure analysis. One of the remaining 11 patients had local failure at 6 months. Three patients had distant intracranial failure at 6, 8 and 9 months. No patient had wound complications or radiation necrosis that required surgical intervention. We report the first experience using Cs131 brachytherapy in patients with recurrent HGG. Cs 131 implant may be considered a safe and effective treatment in this group of patients with limited salvage options.
A Restless Leg Syndrome Incidentally Detected by an 18F-FDG Positron Emission Tomography
Authors: Jessica Ohnona, Arnaud Metlaine, Damien Leger, Jean-Noël Talbot
Journal: Clinical Nuclear Medicine (2017)

A case of a restless leg syndrome (RLS) was incidentally detected in a 49-year-old woman referred for an F-FDG PET/CT in monitoring her breast cancer. She was treated with chemotherapy and on long-term hormone therapy. Diffuse F-FDG uptake of calf muscles was visualized. Medical history revealed that the patient felt leg cramps in supine position, suggesting RLS. The diagnosis was confirmed using clinical rating scales and polysomnography. RLS being underdiagnosed, this type of FDG PET/CT incidental finding should prompt to check the presence of evocative symptoms and refer the patient to a physician specialized in sleep disorders.
The effect of a transition into poverty on child and maternal mental health: a longitudinal analysis of the UK Millennium Cohort Study
Authors: Sophie Wickham, Margaret Whitehead, David Taylor-Robinson, Ben Barr
Journal: The Lancet Public Health (2017)

Whether or not relative measures of income poverty effectively reflect children's life chances has been the focus of policy debates in the UK. Although poverty is associated with poor child and maternal mental health, few studies have assessed the effect of moving into poverty on mental health. To inform policy, we explore the association between transitions into poverty and subsequent mental health among children and their mothers.In this longtitudinal analysis, we used data from the UK Millennium Cohort Study, a large nationally representative cohort of children born in the UK between Sept 1, 2000, and Jan 11, 2002, who participated in five survey waves as they progressed from 9 months of age to 11 years of age. Our analysis included all children and mothers who were free from mental health problems and not in poverty when the children were aged 3 years. We only included singletons (ie, not twins or other multiple pregnancies) and children for whom the mother was the main respondent to the study. The main outcomes were child socioemotional behavioural problems (Strengths and Difficulties Questionnaire) at ages 5 years, 7 years, and 11 years and maternal psychological distress (Kessler 6 scale). Using discrete time-hazard models, we followed up families without mental health problems at baseline and estimated odds ratios for subsequent onset of maternal and child mental health problems associated with first transition into poverty, while adjusting for confounders, including employment transitions. We further assessed whether or not change in maternal mental health explained any effect on child mental health.Of the 6063 families in the UK Millennium Cohort study at 3 years who met our inclusion criteria, 844 (14%) had a new transition into poverty compared with 5219 (86%) who remained out of poverty. After adjustment for confounders, transition into poverty increased the odds of socioemotional behavioural problems in children (odds ratio 1·41 [95% CI 1·02-1·93]; p=0·04) and maternal psychological distress (1·44 [1·21-1·71]; p<0·0001). Controlling for maternal psychological distress reduced the effect of transition into poverty on socioemotional behavioural problems in children (1·30 [0·94-1·79]; p=0·11).In a contemporary UK cohort, first transition into income poverty during early childhood was associated with an increase in the risk of child and maternal mental health problems. These effects were independent of changes in employment status. Transitions to income poverty do appear to affect children's life chances and actions that directly reduce income poverty of children are likely to improve child and maternal mental health.The Wellcome Trust and The Farr Institute for Health Informatics Research (Medical Research Council).
Attitudes to the return of incidental and targeted genomic findings obtained in a high-risk pediatric cancer versus an inherited genetic condition research setting.
Authors: Conrad Vincent Fernandez, Nada Jabado, Kym Boycott, David Malkin, Eric Bouffet, Colleen O'Connell, Denise Avard, Bartha Knoppers, Poul Sorensen, Andrew C Orr, Christopher McMaster
Journal: Journal of Clinical Oncology (2013)

10066 Background: The disclosure of clinically significant, validated incidental and target findings to participants in genomic research is often recommended. There have been no reports on whether attitudes of parents differ if these findings emerge from an acquired pediatric cancer versus an inherited genetic condition setting. Methods: Parents in 3 large-scale projects [Canadian Pediatric Cancer Genome Consortium (CPCGC), the Finding of Rare Genes Canada Consortium (FORGE) and the Orphan Diseases: identifying Genes and Novel Therapeutics to Enhance Treatment Project (IGNITE)] were surveyed using a mailed, validated 29-item questionnaire. Two reminders were sent. Analysis was by descriptive and Chi-square statistics. Results: Response rate: 64% (n=307/480). 40% were &gt; 50 yrs age; more than half had a grade 12 education. 86 were parents of poor risk pediatric cancer patients and 221 were parents or individuals with rare inherited conditions. Most stated a very strong or strong right to genomic research results, irrespective if from the target condition (97%) or incidental (86%). 70% wish genetic counselling pre- and post-research testing; an additional 20% were uncertain what this entails. Almost all indicated that genomic research for childhood onset conditions should occur, regardless of whether therapy existed (99%) or not (91%). A few indicated that they would not want incidental results showing an untreatable fatal condition (17%). Most want results, even if these suggest susceptibility to multiple conditions (87%) or are of uncertain health impact (84%). Most felt a right to genomic research that showed a serious condition in siblings, whether treatable (94%) or not (89%). 74% strongly support that results discovered after death of the proband be shared with family. Conclusions: Parents of children in both cancer and inherited rare conditions genomic research do not differ in indicating a strong right and desire to receive research results, even if they are of uncertain impact, of childhood onset, or after death of the proband. Clear delineation of what will or will not be offered from genomic research should be established at the time of consent.
Predictive factors for T790M mutation in plasma in patients after progression to 1st line tyrosine-kinase inhibitor (TKI) with or without subsequent lines of TKI or chemotherapy for metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)
Authors: K.-S. Lau, T.-H. So, T.-S. Choy, D.K. Leung, K.-O. Lam, P.Y.P. Ho, W.-L. Chan, L.-S. Wong, S.-Y. Chan, F.-T. Chan, R.P. Tse, C.-W. Choi, T.-C. Lam, D.W. Kwong, A. Lee, T.-W. Leung, V.H. Lee
Journal: Annals of Oncology (2016)
Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients
Authors: Fabio Efficace, Michele Baccarani, Massimo Breccia, Giuliana Alimena, Gianantonio Rosti, Giorgio Lambertenghi Deliliers, Claudia Baratè, Antonella Russo Rossi, Giuseppe Fioritoni, Luigia Luciano, Diamante Turri, Francesco Nobile, Francesco Di Raimondo, Antonio Cuneo, Marco Gobbi, Pietro Leoni, Maria Pina Simula, Luciano Levato, Giuseppe Saglio, Dino Veneri, Giuseppe Leone, Alessandro Rambaldi, Simonetta Pardini, Filippo Gherlinzoni, Alfonso Zaccaria, Mario Tiribelli, Francesco Cottone, Marco Vignetti, Franco Mandelli
Journal: Blood (2010)
Targeting XIAP and ARC (apoptosis repressor with caspase recruitment domain) Overcomes Imatinib Resitance In Blast Crisis CML Cells.
Authors: Bing Carter, Duncan H. Mak, Wendy D. Schober, Marina Konopleva, Jorge E. Cortes, Hagop M. Kantarjian, Erich Koller, Ziwei Huang, John C. Reed, Michael Andreeff
Journal: Blood (2010)
A phase I trial to assess the safety, PK and PD of CXD101 in advanced cancer expressing the biomarker HR23B
Authors: T.A. Eyre, G.P. Collins, A. Gupta, S. Sheikh, V. Woodcock, J. Whittaker, L.M. Wang, E. Soilleux, F. Tysoe, R. Cousins, N.L.a. Thangue, D. Kerr, M.R. Middleton
Journal: Annals of Oncology (2016)